Cagrilintide is a weight management research compound currently in stock directly from a verified Chinese manufacturer. Every batch is HPLC-verified and shipped with a Certificate of Analysis (COA). Sourcing is direct — no intermediaries. Minimum order value is $600 USD. International shipping available.
Cagrilintide is a long-acting acylated amylin analogue developed for metabolic research. Structurally derived from human amylin (IAPP — islet amyloid polypeptide), it is modified with a C20 fatty diacid chain to extend its plasma half-life to approximately 7 days, enabling once-weekly administration in clinical protocols. Research interest centers on its action at amylin receptors (AMY1, AMY2, AMY3) in the hypothalamus and area postrema, which are distinct from the GLP-1 receptor pathway targeted by semaglutide and related compounds.
Preclinical and early clinical studies have examined cagrilintide's role in energy intake regulation, gastric emptying rate, and glucagon suppression. Unlike GLP-1 receptor agonists, amylin analogues appear to act via complementary central pathways, with satiety signals mediated through hindbrain amylin receptor populations. This mechanistic distinction has generated research interest in dual-agonism approaches combining amylin and GLP-1 receptor activity — most notably in the CagriSema combination, currently in phase 3 clinical evaluation.
PeptidesFromChina.co supplies cagrilintide as a lyophilized powder in sealed vials at 99%+ purity, verified by HPLC and Mass Spectrometry. Certificate of Analysis accompanies every batch. All products are supplied for laboratory research use only and are not for human consumption.
| Chemical Class | Acylated amylin analogue |
|---|---|
| Synonyms | IcoSema amylin component, AM833 |
| Amino Acids | 26 (modified human amylin sequence) |
| Molecular Weight | ~3367 Da (with C20 fatty acid modification) |
| CAS Number | 2173468-47-0 |
| Research Areas | Metabolic regulation, appetite signaling, gastric emptying, amylin receptor pharmacology |
| Receptor Target | AMY1, AMY2, AMY3 (amylin receptor subtypes) |
| Form | Lyophilized powder |
| Storage | −20°C long-term; 2-8°C aqueous (short-term, use promptly) |
| Molecular Formula | N/A — acylated analogue of amylin; see COA |
| Sequence | Available on COA (37-aa amylin analogue, C18 fatty-diacid acylation) |
| Name | Strength | Pack Size | Purity | Availability | Price (USD) |
|---|---|---|---|---|---|
| Cagrilintide | 5 mg | 10 vials | ≥98% | In Stock | $113.00 |
| Cagrilintide | 10 mg | 10 vials | ≥98% | In Stock | $200.00 |
Testing method: HPLC / LC-MS (["HPLC","LC-MS","Endotoxins","Microbiology","Water Content"]). Every batch is tested before shipment. Purity ≥99% confirmed per batch.
Certificate of Analysis: Manufacturer COA. Documentation is available for every batch sold.
Cagrilintide binds amylin receptor complexes (AMY1-3), which are heterodimers of the calcitonin receptor and receptor activity-modifying proteins (RAMPs). Research has focused on how fatty acid acylation affects receptor binding affinity, selectivity between AMY subtypes, and duration of action compared to native human amylin and earlier analogues. The long half-life achieved through acylation is a primary pharmacokinetic research interest.
Studies have examined cagrilintide's effects on food intake in diet-induced obesity rodent models. Proposed mechanisms include signaling through hindbrain amylin receptors in the area postrema and nucleus tractus solitarius, regions involved in satiety processing. Complementary action with GLP-1 receptor agonists at distinct central sites has been a key hypothesis driving combination research.
Research has examined cagrilintide's influence on gastric emptying, glucagon secretion, and body weight outcomes in preclinical models. Its metabolic profile — distinct from GLP-1, GIP, or glucagon receptor pathways — positions it as a tool compound for studying amylinergic contributions to energy homeostasis independent of incretin signaling.
Cagrilintide is an amylin analogue targeting AMY1-3 receptors, while semaglutide is a GLP-1 receptor agonist. They operate via distinct receptor systems and central signaling pathways — making them mechanistically complementary in metabolic research rather than interchangeable.
CagriSema is the clinical name for the co-administration of cagrilintide and semaglutide in a fixed-ratio combination. It combines amylin receptor agonism (cagrilintide) and GLP-1 receptor agonism (semaglutide) in a single research protocol. Both components are available separately through PeptidesFromChina.co.
Cagrilintide is synthesized to 99%+ purity, verified by HPLC and Mass Spectrometry. Certificate of Analysis from the manufacturing facility is included with every batch.
Lyophilized cagrilintide should be stored at −20°C, protected from light and moisture. Reconstituted solutions should be kept at 2-8°C and used promptly due to the acylated modification.
For laboratory research use only. Not for human or veterinary use. PeptidesFromChina.co is a B2B wholesale supplier operating under strict research-use-only terms. All products are sold exclusively for in vitro and preclinical research purposes.